The operational questions that should dominate a biopharma due diligence
In biopharma transactions, operational due diligence is often the difference between a successful investment and an expensive surprise. Financial performance, market opportunity, and pipeline potential remain critical evaluation areas, but operational realities ultimately determine whether an organization can consistently manufacture, scale, comply, and deliver commercial value. In highly regulated environments, operational weaknesses rarely remain isolated. […]
Why Most CDMO Performance Problems Are Governance Problems?
In biopharmaceutical manufacturing, operational challenges are often blamed on capacity constraints, technical complexity, staffing shortages, or supply chain disruption. While these factors certainly play a role, many persistent CDMO performance issues stem from a more fundamental problem: weak governance. Missed timelines, recurring deviations, slow decision-making, unclear accountability, and strained client relationships are frequently symptoms of […]
Practical Operational Excellence: Building Improvement That Sticks
Manufacturing and operational organisations across many industries invest heavily in operational improvement. Lean deployments, Six Sigma programmes, visual management systems, and culture-change initiatives are common. The investment is real, and the intentions are usually good. Yet experienced operations leaders will recognise a recurring problem: much of the improvement does not last. Twelve months after the […]